Neumora Therapeutics, Inc.
NMRAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Neumora Therapeutics, Inc. focuses on Biotechnology services and products. Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in. The company carries a $246.1M market cap, placing it firmly in the micro-cap category. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Market Cap
$246.1M
Beta
2.74
P/E (TTM)
—
P/E (Fwd)
-1.96
EPS (TTM)
$-1.20
EPS (Fwd)
$-0.67
ROE
-187.1%
ROA
-73.9%
Cash
$116.8M
Total Debt
$53.3M
Free CF
-$99.4M
52W Change
-18.7%
Annual Financials
Cash vs Debt
Where NMRA stands vs its 150-day and 200-day moving averages
As of the August 20, 2026 close, NMRA finished 22.27% below its 150-day moving average ($2.11) and 23.36% below its 200-day moving average ($2.14). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NMRA overbought or oversold?
At the August 20, 2026 close, NMRA's RSI(14) was 49.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $116.8M in cash comfortably exceeding the $53.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$99.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -187.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Neumora Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, NMRA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing NMRA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.